| 초록 |
Background: Adequate regulation of phosphorus in chronic kidney disease (CKD) is considered important
because of its association with bone mineral metabolism. The present study aimed to determine the effects of
cholecalciferol administration in patients with CKD by investigating the relationship between the serum calcidiol
(25(OH)D3) level and the change in the renal phosphate reabsorption threshold. The relationship was assessed
using the ratio of the maximum rate of tubular phosphate reabsorption to the glomerular filtration rate
(TmP/GFR), which can be calculated with the levels of serum, urine phosphate, and creatinine.
Methods: The study included 116 patients with predialysis stage 1–5 CKD who received cholecalciferol. In all
patients, the phosphate, creatinine, calcium, intact parathyroid hormone, and 25(OH)D3 levels were measured 1
year before and after cholecalciferol administration. The TmP/GFR ratio was calculated using a simple
algorithm.
Results: There was no correlation between the TmP/GFR ratio and the 25(OH)D3 level in the patients. In
subgroup analysis, patients with a decline in the TmP/GFR ratio from 1 year previously to the time of
administration showed a positive correlation between ΔTmP/GFR and Δ25(OH)D3 after cholecalciferol
administration (p = 0.044).
Conclusion: Cholecalciferol administration might increase the TmP/GFR ratio and 25(OH)D3 level in CKD
patients with deterioration of bone mineral metabolism. Additionally, 25(OH)D3 may be beneficial for the
progression of mineral metabolism, as it can alter the TmP/GFR ratio.
Figures: |